DE2501091A1 - 17-alpha-aethinyl-(5-alpha)-2-androsten-17-beta-ol und sein 17-beta-acetat, verfahren zu ihrer herstellung und ihre therapeutische verwendung - Google Patents
17-alpha-aethinyl-(5-alpha)-2-androsten-17-beta-ol und sein 17-beta-acetat, verfahren zu ihrer herstellung und ihre therapeutische verwendungInfo
- Publication number
- DE2501091A1 DE2501091A1 DE19752501091 DE2501091A DE2501091A1 DE 2501091 A1 DE2501091 A1 DE 2501091A1 DE 19752501091 DE19752501091 DE 19752501091 DE 2501091 A DE2501091 A DE 2501091A DE 2501091 A1 DE2501091 A1 DE 2501091A1
- Authority
- DE
- Germany
- Prior art keywords
- androsten
- delta
- compound
- acetate
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 18
- 230000001225 therapeutic effect Effects 0.000 title description 9
- 238000004519 manufacturing process Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 24
- 210000001672 ovary Anatomy 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000002611 ovarian Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 210000002374 sebum Anatomy 0.000 claims description 7
- 210000004291 uterus Anatomy 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000004907 gland Anatomy 0.000 claims description 6
- 230000036512 infertility Effects 0.000 claims description 5
- 208000015124 ovarian disease Diseases 0.000 claims description 5
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 5
- 206010001233 Adenoma benign Diseases 0.000 claims description 4
- 239000003810 Jones reagent Substances 0.000 claims description 4
- 206010039792 Seborrhoea Diseases 0.000 claims description 4
- 208000011622 Testicular disease Diseases 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- ISJVDMWNISUFRJ-HKQXQEGQSA-N (5s,8r,9s,10s,13s,14s)-10,13-dimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1C=CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 ISJVDMWNISUFRJ-HKQXQEGQSA-N 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000003076 Osteolysis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010036940 Prostatic adenoma Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 208000007659 Fibroadenoma Diseases 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 1
- 244000007853 Sarothamnus scoparius Species 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229940127234 oral contraceptive Drugs 0.000 claims 1
- 239000003539 oral contraceptive agent Substances 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 10
- 239000000262 estrogen Substances 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 230000001817 pituitary effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- CGFFKDRVHZIQHL-UHFFFAOYSA-N 1-but-3-en-2-yl-3-(methylcarbamothioylamino)thiourea Chemical compound CNC(=S)NNC(=S)NC(C)C=C CGFFKDRVHZIQHL-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000016087 ovulation Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000004451 Pituitary Gonadotropins Human genes 0.000 description 6
- 108010081865 Pituitary Gonadotropins Proteins 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 210000002149 gonad Anatomy 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010062767 Hypophysitis Diseases 0.000 description 5
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 5
- 229960003608 clomifene Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 230000002710 gonadal effect Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000002747 omentum Anatomy 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- VOXZDWNPVJITMN-QXDIGNSFSA-N (8s,9r,13r,14r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@@H]3CC[C@@](C)([C@@H](CC4)O)[C@H]4[C@H]3CCC2=C1 VOXZDWNPVJITMN-QXDIGNSFSA-N 0.000 description 1
- ISJVDMWNISUFRJ-HQEMIIEJSA-N 5α-androst-2-ene-17-one Chemical compound C1C=CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC21 ISJVDMWNISUFRJ-HQEMIIEJSA-N 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000003517 anti-gonadal effect Effects 0.000 description 1
- 230000000733 anti-osteolytic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000002054 antogonadotrophic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2211/74A GB1492746A (en) | 1974-01-17 | 1974-01-17 | Androstane derivatives and compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2501091A1 true DE2501091A1 (de) | 1975-07-24 |
Family
ID=9735557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752501091 Pending DE2501091A1 (de) | 1974-01-17 | 1975-01-13 | 17-alpha-aethinyl-(5-alpha)-2-androsten-17-beta-ol und sein 17-beta-acetat, verfahren zu ihrer herstellung und ihre therapeutische verwendung |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS576439B2 (enExample) |
| AR (1) | AR203672A1 (enExample) |
| AU (1) | AU521392B2 (enExample) |
| BE (1) | BE823594A (enExample) |
| BR (1) | BR7500346A (enExample) |
| CA (1) | CA1065851A (enExample) |
| CH (1) | CH606091A5 (enExample) |
| DE (1) | DE2501091A1 (enExample) |
| DK (1) | DK135538B (enExample) |
| ES (1) | ES433677A1 (enExample) |
| FR (1) | FR2258185B1 (enExample) |
| GB (1) | GB1492746A (enExample) |
| IE (1) | IE40477B1 (enExample) |
| IT (1) | IT1044268B (enExample) |
| LU (1) | LU71662A1 (enExample) |
| NL (1) | NL183402C (enExample) |
| PH (1) | PH15366A (enExample) |
| SE (1) | SE7500479L (enExample) |
| ZA (1) | ZA75254B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE19781T1 (de) * | 1981-06-02 | 1986-05-15 | Theramex | Androstenen enthaltenden pharmazeutische zusammensetzungen. |
| JPS60173248A (ja) * | 1984-02-16 | 1985-09-06 | 三晃金属工業株式会社 | 嵌合外囲体 |
| US5116830A (en) * | 1984-08-17 | 1992-05-26 | Sri International | Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses |
| WO1986001208A1 (en) * | 1984-08-17 | 1986-02-27 | Sri International | Stereoisometrically pure 17-alpha-ethynyl-estra-2-en-17beta-ol and esters thereof |
| DE3661832D1 (en) * | 1985-04-29 | 1989-02-23 | Theramex | Process for the preparation of pure androst-2-ene derivatives |
| FR2598083B1 (fr) * | 1986-05-05 | 1989-12-29 | Theramex Laboratoire | Nouvelles compositions pharmaceutiques a action antiprogesteronique et leur procede d'obtention |
| RU2652702C2 (ru) | 2016-10-19 | 2018-04-28 | Игорь Ву-Юнович Ван | Субатмосферная система теплохолодоснабжения |
-
1974
- 1974-01-17 GB GB2211/74A patent/GB1492746A/en not_active Expired
- 1974-12-18 CH CH1734774A patent/CH606091A5/xx not_active IP Right Cessation
- 1974-12-19 BE BE151716A patent/BE823594A/xx unknown
- 1974-12-30 DK DK690574AA patent/DK135538B/da not_active IP Right Cessation
- 1974-12-31 FR FR7443397A patent/FR2258185B1/fr not_active Expired
-
1975
- 1975-01-09 ES ES433677A patent/ES433677A1/es not_active Expired
- 1975-01-13 DE DE19752501091 patent/DE2501091A1/de active Pending
- 1975-01-14 ZA ZA00750254A patent/ZA75254B/xx unknown
- 1975-01-14 JP JP698075A patent/JPS576439B2/ja not_active Expired
- 1975-01-15 AU AU77335/75A patent/AU521392B2/en not_active Expired
- 1975-01-16 SE SE7500479A patent/SE7500479L/xx unknown
- 1975-01-16 PH PH16719A patent/PH15366A/en unknown
- 1975-01-16 CA CA218,033A patent/CA1065851A/fr not_active Expired
- 1975-01-16 LU LU71662A patent/LU71662A1/xx unknown
- 1975-01-16 IT IT19319/75A patent/IT1044268B/it active
- 1975-01-17 NL NLAANVRAGE7500608,A patent/NL183402C/xx not_active IP Right Cessation
- 1975-01-17 AR AR257331A patent/AR203672A1/es active
- 1975-01-17 BR BR346/75A patent/BR7500346A/pt unknown
- 1975-01-17 IE IE83/75A patent/IE40477B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE40477B1 (en) | 1979-06-06 |
| NL183402C (nl) | 1988-10-17 |
| IT1044268B (it) | 1980-03-20 |
| DK135538C (enExample) | 1977-10-24 |
| DK690574A (enExample) | 1975-09-29 |
| DK135538B (da) | 1977-05-16 |
| PH15366A (en) | 1982-12-10 |
| JPS576439B2 (enExample) | 1982-02-04 |
| IE40477L (en) | 1975-07-17 |
| CA1065851A (fr) | 1979-11-06 |
| LU71662A1 (enExample) | 1975-06-24 |
| AU521392B2 (en) | 1982-04-01 |
| FR2258185A1 (enExample) | 1975-08-18 |
| AU7733575A (en) | 1976-07-15 |
| GB1492746A (en) | 1977-11-23 |
| CH606091A5 (enExample) | 1978-10-13 |
| NL7500608A (nl) | 1975-07-21 |
| ES433677A1 (es) | 1976-11-16 |
| BR7500346A (pt) | 1975-11-04 |
| ZA75254B (en) | 1976-01-28 |
| BE823594A (fr) | 1975-04-16 |
| NL183402B (nl) | 1988-05-16 |
| SE7500479L (enExample) | 1975-07-18 |
| FR2258185B1 (enExample) | 1978-07-28 |
| AR203672A1 (es) | 1975-09-30 |
| JPS50106952A (enExample) | 1975-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69125714T2 (de) | Zusammensetzung für die behandlung des humanen prostata adenokarzinom | |
| DE3688001T2 (de) | Fruchtbarkeitsmittel enthaltend extrakte von coix lacryma-jobi oder ferulylstanolderivate und/oder fettsaeure-phytosterolester. | |
| DE2643936A1 (de) | Arzneimittel mit erythropoietischer wirksamkeit | |
| DE2501091A1 (de) | 17-alpha-aethinyl-(5-alpha)-2-androsten-17-beta-ol und sein 17-beta-acetat, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| Willestaedt et al. | Studies in osteogenesis | |
| DE2610497C2 (de) | In 16-Stellung disubstituierte 3- Ketosteroide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2215499C2 (de) | Diäther des Östradiol | |
| DE69518258T2 (de) | Kortikoidderivate und pharmazeutische und kosmetische Zusammensetzungen | |
| DE2109853C3 (enExample) | ||
| DE2539824A1 (de) | Pharmazeutische zubereitung | |
| DE69906575T2 (de) | Isoliertes material mit anti-organotropischer wirkung | |
| DE3490728C2 (de) | Androstan-Derivate | |
| DE2508775C2 (de) | 3-oxo-17&beta;-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung | |
| DE2037403C3 (de) | 3-OXO-7 a , 17 a -dimethyl- 13 ß -äthyl-17 ß -hydroxy-gona-4,9,11-trien, Verfahren zu seiner Herstellung, dabei auftretende Zwischenprodukte sowie Arzneimittel | |
| DE1468681C3 (de) | 17beta-Tetrahydropyranyloxy verbindungen der Androstanreihe sowie Verfahren zu ihrer Herstellung und Heilmittel | |
| DE2037155A1 (enExample) | ||
| DE1468919C (de) | 3,11 Dioxo steroid 4,9 diene und ein Verfahren zu ihrer Herstellung | |
| DE1808425C (de) | 3 Oxo 17beta hydroxy 17 alpha (but 2 myl> 13 beta C tief 1 bis C tief 3 alkyl gona 4,9,11 tnene | |
| DE2323615A1 (de) | Zootechnische zusammensetzungen | |
| DE1593204C (de) | 19-nor-Delta hoch 4,6 -3,20-Diketosteroide, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE1568372C3 (de) | 7 alpha-Äthylthio-17 beta-hydroxy-17 alpha-methyl-5-alpha androstane eckige Klammer auf 3,2-C eckige Klammer zu pyrazol und Verfahren zu seiner Herstellung | |
| DE2344749A1 (de) | Arzneimittel auf basis von androst3-en-17-ol und seinen estern | |
| AT379596B (de) | Verfahren zur herstellung eines neuen polypeptids | |
| DE2147309A1 (de) | Arzneimittel auf basis von dehydroepiandrosteronestern | |
| DE1087596B (de) | Verfahren zur Herstellung eines 19-Nortestosteron-17-fettsaeureesters mit lang anhaltender anaboler Wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |